BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18303433)

  • 41. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
    Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
    Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.
    Patz EF; Connolly J; Herndon J
    AJR Am J Roentgenol; 2000 Mar; 174(3):769-74. PubMed ID: 10701623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
    Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
    Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
    Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
    Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
    J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey.
    Morgensztern D; Ng SH; Gao F; Govindan R
    J Thorac Oncol; 2010 Jan; 5(1):29-33. PubMed ID: 19952801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Value of positron emission tomography for lung cancer staging.
    Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
    Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
    Eschmann SM; Friedel G; Paulsen F; Budach W; Harer-Mouline C; Dohmen BM; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trends in the Use of (18)F-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer.
    Veenstra CM; Vachani A; Ciunci CA; Zafar HM; Epstein AJ; Paulson EC
    J Am Coll Radiol; 2016 May; 13(5):491-6. PubMed ID: 26774883
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
    Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
    Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
    Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
    Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 58. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
    Hicks RJ; Kalff V; MacManus MP; Ware RE; Hogg A; McKenzie AF; Matthews JP; Ball DL
    J Nucl Med; 2001 Nov; 42(11):1596-604. PubMed ID: 11696627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estimation of Recurrence Risk After Normal (18)F-FDG PET/CT in Nonsmall-Cell Lung Cancer.
    Pak K; Kim SJ; Koo PJ; Chang S
    Cancer Biother Radiopharm; 2016 Jun; 31(5):174-9. PubMed ID: 27310304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review.
    Nair VS; Krupitskaya Y; Gould MK
    J Thorac Oncol; 2009 Dec; 4(12):1473-9. PubMed ID: 19887967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.